



IFW 1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Christian P. Larsen et al.
Serial No.: 10/057,288
Filed: January 25, 2002
Docket: D0136NP/30436.58USU1
Title: METHODS OF INDUCING ORGAN TRANSPLANT TOLERANCE AND CORRECTING HEMOGLOBINOPATHIES USING L104EA29YIg IN CONJUNCTION WITH AN ALKYLATING AGENT

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 1, 2006.

By: Renato Marco P. Domingo
Name: Renato Marco P. Domingo

55 S. Lake Avenue, Suite 710
Pasadena, California 91101
June 1, 2006

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR §1.8
- ☒ Supplemental Information Disclosure Statement (37 C.F.R. §1.97 (b)(4))
- ☒ Form 1449 (Information Disclosure Statement)
- ☒ Exhibits 271-274
- ☒ Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO
55 South Lake Avenue, Suite 710
Pasadena, California 91101
(626) 395-7801

By: Sarah B. Adriano
Name: Sarah B. Adriano
Reg. No.: 34,470
Initials: SBA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Christian P. Larsen et al. **Examiner:** P. Gambel
Serial No.: 10/057,288 **Group Art Unit:** 1644
Filed: January 25, 2002 **Docket No.:** D0136NP/30436.58USU1
Title: METHODS OF INDUCING ORGAN TRANSPLANT TOLERANCE AND
CORRECTING HEMOGLOBINOPATHIES USING L104EA29YIg IN
CONJUNCTION WITH AN ALKYLATING AGENT

CERTIFICATE UNDER 37 CFR §1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 1, 2006.

By: Renato Marco P. Domingo
Name: Renato Marco P. Domingo

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
(37 C.F.R. § 1.97(b)(4))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed herein as a supplement to Applicant's July 31, 2002, January 15, 2003, June 13, 2003, February 27, 2004, February 28, 2005 and March 21, 2005 Information Disclosure Statements which were submitted under 37 C.F.R. §§1.97(b)(3) and (c) before the mailing date of the first Office Action on the merits. The references cited herein were first cited in the Australian Official Report in connection with a related Australian patent application, and are being cited within three months from the date of the issuance of the Official Report, i.e. March 22, 2006. In accordance with 37 C.F.R. §1.98(d), copies of Exhibits 271-274 as set forth in the Form 1449 are included herein.

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. These are as follows:


- Haddad, Elie et al., "Long-Term Chimerism and B-Cell Function After Bone Marrow Transplantation in Patients with Severe Combined Immunodeficiency with B Cells: A Single-Center Study of 22 Patients," *Blood*, 1999, 94:2923-30 – **Exhibit 271**
- Marks, David I. et al., "T Cell-Depleted Unrelated Donor Bone Marrow Transplantation for Acute Myeloid Leukemia," *Biology of Blood and Marrow Transplantation*, 2000, 6:646-53 – **Exhibit 272**
- Or, R. et al., "Bone Marrow Transplantation in b-Thalassemia Major: the Israeli Experience," *Hemoglobin*, 1988, 12:609-14 – **Exhibit 273**
- Tomita, Yukihiro et al., "Induction of Permanent Mixed Chimerism and Skin Allograft Tolerance Across Fully MHC-Mismatched Barriers by the Additional Myelosuppressive Treatments in Mice Primed with Allogeneic Spleen Cells Followed by Cyclophosphamide," *Journal of Immunology*, 2000, 164:34-41 – **Exhibit 274**

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that the references have been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Applicants invite the Patent Office to request additional information if necessary. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

No fee, other than the \$180.00 fee under 37 C.F.R. §1.17(p), is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-0306.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Sarah B. Adriano", with a horizontal line drawn underneath it.

Sarah B. Adriano
Registration No. 34,470
SaraLynn Mandel
Registration No. 31,853
Mandel & Adriano
55 South Lake Avenue, Suite 710
Pasadena, California 91101
(626) 395-7801
Customer No. 26,941

FORM 1449*

Docket Number

D0136NP/30436.58USU1

Application Number

10/057,288

Applicants

Christian P. Larsen et al.

Filing Date

January 25, 2002

Group Art Unit

1644

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

